CEREBAIN BIOTECH CORP. (OTCMKTS:CBBT) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors, Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
Resignation of Wesley D. Tate
On July 1, 2019, Mr. Wesley D. Tate informed the Board of Directors (the “Board”) of Cerebain Biotech Corp. (the “Company”), that he was resigning as the Company’s Chief Financial Officer, Chief Operating Officer and as a member of its Board of Directors, effective July 15, 2019. Mr. Tate’s resignation was not the result of any disagreement with the Company on any matter relating to the Company’s operations, policies or practices.
Item 9.01. Financial Statements and Exhibits.
__________
* filed herewith
CEREBAIN BIOTECH CORP. Exhibit
EX-17.1 2 cbbt_ex171.htm LETTER OF RESIGNATION cbbt_ex171.htmEXHIBIT 17.1 July 1,…
To view the full exhibit click here
About CEREBAIN BIOTECH CORP. (OTCMKTS:CBBT)
Cerebain Biotech Corp. is a biomedical company. The Company operates as a development-stage medical device company focused on the creation and clinical development of a minimally invasive implantable device. The Company, through its subsidiary, Cerebain Operating, Inc., is involved in the discovery of products for the treatment of Alzheimer’s disease utilizing Omentum. The Omentum is a layer of tissue lying over internal organs (such as the intestines) and has the ability to generate biological agents that nourish nerves and help them grow. The Company is focused on inclusion of both a medical device solution, as well as a synthetic drug solution in its products. The Company is in the process of preparing for initial clinical trials.